In summary, METTL16 drives CCA progression through m6A-dependent regulation of PRDM15 and ATF4, maintaining mitochondrial integrity and inhibiting ferroptosis, highlighting its potential as a prognostic biomarker and therapeutic target. Here, METTL16 is linked to cholangiocarcinoma.